Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients

Next Previous
Trial Profile

Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms VIP

    • Most Recent Events

    • 19 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top